Advances in diabetes for the millennium

Diabetes and cholesterol CME

Marc Rendell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The development of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has made it possible to significantly lower cholesterol and low-density lipoprotein (LDL) levels. A moderate reduction of LDL levels has resulted in substantial decreases on the order of 30% to 40% in cardiovascular mortality. It is yet unknown whether a reduction of cholesterol levels below normal levels can counteract the increased cardiovascular mortality associated with diabetes. Studies thus far do demonstrate at least as much benefit in diabetic as in nondiabetic patients from cholesterol-lowering therapy. Pharmacologic therapy does have side effects. It is important to consider possible adverse effects as we progressively increase the dosage levels of various agents to meet the continually dropping LDL target levels in diabetic patients.

Original languageEnglish
JournalMedGenMed Medscape General Medicine
Volume6
Issue number3 SUPPL.
StatePublished - 2004

Fingerprint

LDL Lipoproteins
Cholesterol
Mortality
LDL Cholesterol
Oxidoreductases
Therapeutics
3-hydroxy-3-methylglutaryl-coenzyme A

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Advances in diabetes for the millennium : Diabetes and cholesterol CME. / Rendell, Marc.

In: MedGenMed Medscape General Medicine, Vol. 6, No. 3 SUPPL., 2004.

Research output: Contribution to journalArticle

@article{65bf8e818ac1489a9282f0cb923a08e7,
title = "Advances in diabetes for the millennium: Diabetes and cholesterol CME",
abstract = "The development of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has made it possible to significantly lower cholesterol and low-density lipoprotein (LDL) levels. A moderate reduction of LDL levels has resulted in substantial decreases on the order of 30{\%} to 40{\%} in cardiovascular mortality. It is yet unknown whether a reduction of cholesterol levels below normal levels can counteract the increased cardiovascular mortality associated with diabetes. Studies thus far do demonstrate at least as much benefit in diabetic as in nondiabetic patients from cholesterol-lowering therapy. Pharmacologic therapy does have side effects. It is important to consider possible adverse effects as we progressively increase the dosage levels of various agents to meet the continually dropping LDL target levels in diabetic patients.",
author = "Marc Rendell",
year = "2004",
language = "English",
volume = "6",
journal = "MedGenMed Medscape General Medicine",
issn = "1531-0132",
publisher = "Medscape Health Network",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Advances in diabetes for the millennium

T2 - Diabetes and cholesterol CME

AU - Rendell, Marc

PY - 2004

Y1 - 2004

N2 - The development of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has made it possible to significantly lower cholesterol and low-density lipoprotein (LDL) levels. A moderate reduction of LDL levels has resulted in substantial decreases on the order of 30% to 40% in cardiovascular mortality. It is yet unknown whether a reduction of cholesterol levels below normal levels can counteract the increased cardiovascular mortality associated with diabetes. Studies thus far do demonstrate at least as much benefit in diabetic as in nondiabetic patients from cholesterol-lowering therapy. Pharmacologic therapy does have side effects. It is important to consider possible adverse effects as we progressively increase the dosage levels of various agents to meet the continually dropping LDL target levels in diabetic patients.

AB - The development of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has made it possible to significantly lower cholesterol and low-density lipoprotein (LDL) levels. A moderate reduction of LDL levels has resulted in substantial decreases on the order of 30% to 40% in cardiovascular mortality. It is yet unknown whether a reduction of cholesterol levels below normal levels can counteract the increased cardiovascular mortality associated with diabetes. Studies thus far do demonstrate at least as much benefit in diabetic as in nondiabetic patients from cholesterol-lowering therapy. Pharmacologic therapy does have side effects. It is important to consider possible adverse effects as we progressively increase the dosage levels of various agents to meet the continually dropping LDL target levels in diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=27544498074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544498074&partnerID=8YFLogxK

M3 - Article

VL - 6

JO - MedGenMed Medscape General Medicine

JF - MedGenMed Medscape General Medicine

SN - 1531-0132

IS - 3 SUPPL.

ER -